X

The Envigo brand story

At Envigo, we are proud of our customer-centric culture which makes us responsive to every customer, no matter their size, continually optimizing their research programs to ensure consistently clear results. Learn more

Corporate social responsibility

Corporate social responsibility (CSR) has always been part of the way we’ve done business—it's what we do and how we do it. Learn more

Research models

Use our advanced search tool below to find the exact model you need.

 

Quick Links

Health monitoring reports
Genetic monitoring reports
Cell line references

Successful AAALAC accreditation for Envigo facilities in Barcelona, Spain

In a letter to Envigo, AAALAC notified the company that it had met all the conditions required for full accreditation and commended Envigo employees "for providing and maintaining a high quality program of laboratory animal care and use." Read More

Envigo launches hepatotoxicity testing as part of wider integrated drug development de-risking program

The new Envigo DILI Assessment program can help identify whether a drug exhibits possible risk factors associated with drug induced liver injury. The program can be run in full, using all of its tests, or can be conducted using single assays as required Read More

Envigo CEO: growth strategy, industry challenges

The "double edged sword" of increased regulation is a challenge, but Envigo expects outsourcing to continue as the company looks to diversity its service portfolio. Read More

See All Latest News
Brochure
Envigo oncology brochure (USA | EU)

At Envigo, we understand that our customers conduct research and develop products that have the potential to offer significant improvements to global health and the environment. We also realize achieving that potential has grown more challenging. That is why we remain focused on your goals, needs and expectations, ensuring you have a trusted partner to advance your life-changing research and products.

Article
Developments in LifeSciences Vol. 15, No. 1

In this issue:
• 20 critical questions for ensuring inhaled crop protection and chemical registration
• The CRO landscape — An evolving safety testing market
• Substance identity: The critical component of both lead and co-registrant dossiers
• The extended one-generation reproductive toxicity study (EOGRTS), OECD test guideline 443

Webinar on-demand
Key considerations in the safety evaluation of drugs targeting immune checkpoints

Presented by Lee Coney (Chief Scientific Officer - Biologics) and Mandy Horn (Supervisor - Veterinary Science, Research and Support). You will learn what is cancer immunotherapy; what are the potential challenges in the safety assessment of antibodies targeting immune system checkpoints?; Things to consider when designing and running your nonclinical safety programmes for immune checkpoint targets; and more.

See all insights